"We are excited to expand our technology to be able to capture not only circulating cancer cells from solid tumor and blood cancers but also now to begin to isolate cfDNA and exosomes, as well," said Rolf Muller, BioFluidica's CEO. "We can now employ all important biomarkers on one single liquid biopsy platform, our programmable microfluidic chips. This will have very positive outcomes for personalized medicine in the cancer diagnostics space as we commercialize further, as well as for researchers and patients."
This research is supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R43CA232848 and 1R43CA228923-01A1.
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...
Summary
Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV"). Approval for the delisting was received at...
L.A. Care Health Plan and Blue Shield of California Promise Health Plan today held a grand opening ceremony for their Community Resource Center (CRC) in West Los Angeles (West L.A.) at 11173 W. Pico Blvd in Los Angeles....
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered...